Depression, Depressionen

References ff.

Harden CL, Lazar LM, Pick LH, Nikolov B, Goldstein MA, Carson D, et al (1999a): A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 40:1 129‐ 1134.

Harden CL, et al (l999b, April): Effect of vagus nerve stimula tion on mood in adult epilepsy patients. Paper presented at the 51 St annual meeting of the American Academy of Neurology, Toronto.

Investigational Device Exemptions Manual, Title 21 CFR (1996): Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Devices and Radiological Health (HHS Publication FDA 96-4159).

Keller MB, Shapiro RW, Lavori PW, Wolfe N (1982): Relapse in major depressive disorder: analysis with the life table. Arch Gen Psychiatry 39:911‐915.

Letterman L, Markowitz JS (1999): Gabapentin: A review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Pharmacotherapy 19:565‐572.

Lopez AD, Murray CC (1998): The global burden of disease, 1990-2020. Na! Med 4:1241‐1243.

Montgomery SA, Äsberg M (1979): A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382‐ 389.

Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, et al (1988): The prophylactic efficacy offluoxetine in unipolar depression. Br J Psychiatry 153(suppl 3):69‐76.

Montgomery SA, Dunbar G (1993): Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. In! Clin Psychopharmacol 8:189‐195.

Montgomery SA, Rasmussen JG, Tanghoj P (1993): A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psvchopharmacol 8:181‐188.

Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A (1973): Anti-manic and prophylactic effects of carbamaz epine (Tegretol) on manic depressive psychosis. A prelimi nary report. Folia Psychiatr Neurol Jpn 27:283‐297.

Olfson M, Marcus 5, Sackeim HA, Thompson J, Pincus HA (1998): Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry 155:22‐29.

Oquendo MA, Malone KM, Ellis SP, Sackeim HA, Mann JJ (1999): Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. Am J Psychiatry 156:190‐194.

Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, et al (1996): Resistance to antidepressant medi cations and short-term clinical response to ECT. Am J P.sychiatry 153:985‐992.

Prudic J, Sackeim HA, Devanand DP (1990): Medication resis tance and clinical response to electroconvulsive therapy. Psychiatry Res 31:287‐296.

Quitkin FM, McGrath PJ, Rabkin JG, Stewart JW, Harrison W, Ross DC, et al (1991): Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 148:197‐ 203.

Sackeim HA (1994): Continuation therapy following ECT:

Directions for future research. Psychopharmacol Bull 30:50 1‐52 1.

Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz 5 (1990): The impact of medication resistance and continu ation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psy chopharmacol 10:96‐104.

Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, et al (1993): Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 328:839‐846.

Shapira B, Gorfine M, Lerer B (1995): A prospective study of lithium continuation therapy in depressed patients who have responded to electroconvulsive therapy. Convuls Ther 11:80‐85.

Shea MT, Elkin 1, Imber SD, Sotsky SM, Watkins JT, Collins JF, et al (1992): Course of depressive symptoms over follow-up:

Findings from the National Institute of Mental Health Treat ment of Depression Collaborative Research Program. Arch Gen Psychiatry 49:782‐787.

Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, et al (1997): Depression during mania. Treatment response tu lithium or divalproex. Arch Gen Psychiatry 54:37‐42.

Thase ME, Rush AJ (1995): Treatment resistant depression. In:

Bloom FE, Kupfer DJ, editors. Psychopharmacology: Fourth Generation of Progress. New York: Raven, 1081‐1097.

Vagus Nerve Stimulation Study Group (1995): A randomized controlled trial of chronic vagus nerve stimulation for treat ment of medically intractable seizures. Neurology 45:224‐ 230.

Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R (1999): Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 60:400‐406.

Ware JE Jr, Sherbourne CD (1992): The MOS 36-item short form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 30:473‐483.

Williams JB (1988): A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 45:742‐747.

World Health Organization Drug Dictionary (1999): Uppsala, Sweden: WHO Collaborating Centre for International Drug Monitoring.

Young RC, Biggs JT, Ziegler VE, Meyer DA (1978): A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133:429‐435.